ID   MBK2_CAEEL              Reviewed;         817 AA.
AC   Q9XTF3; H9G2V8; H9G2V9; J7SF89; Q20604; Q27GP3; Q2EEP1; Q9TVF4;
DT   19-JAN-2010, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1999, sequence version 1.
DT   18-JUN-2025, entry version 180.
DE   RecName: Full=Dual specificity tyrosine-phosphorylation-regulated kinase mbk-2 {ECO:0000250|UniProtKB:Q13627};
DE            EC=2.7.12.1 {ECO:0000269|PubMed:17869113, ECO:0000269|PubMed:18199581, ECO:0000269|PubMed:19879842, ECO:0000269|PubMed:25535836};
DE   AltName: Full=Dual specificity Yak1-related kinase mbk-2 {ECO:0000250|UniProtKB:Q13627};
DE   AltName: Full=Minibrain Kinase 2 {ECO:0000303|PubMed:14697358};
GN   Name=mbk-2 {ECO:0000312|WormBase:F49E11.1b};
GN   ORFNames=F49E11.1 {ECO:0000312|WormBase:F49E11.1b};
OS   Caenorhabditis elegans.
OC   Eukaryota; Metazoa; Ecdysozoa; Nematoda; Chromadorea; Rhabditida;
OC   Rhabditina; Rhabditomorpha; Rhabditoidea; Rhabditidae; Peloderinae;
OC   Caenorhabditis.
OX   NCBI_TaxID=6239;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:AAM09088.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM C), SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, DEVELOPMENTAL STAGE, AND DISRUPTION PHENOTYPE.
RX   PubMed=12618396; DOI=10.1093/genetics/163.2.571;
RA   Raich W.B., Moorman C., Lacefield C.O., Lehrer J., Bartsch D.,
RA   Plasterk R.H., Kandel E.R., Hobert O.;
RT   "Characterization of Caenorhabditis elegans homologs of the Down syndrome
RT   candidate gene DYRK1A.";
RL   Genetics 163:571-580(2003).
RN   [2] {ECO:0000305, ECO:0000312|EMBL:CAA94353.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND ALTERNATIVE SPLICING.
RC   STRAIN=Bristol N2 {ECO:0000312|EMBL:CAA94353.1};
RX   PubMed=9851916; DOI=10.1126/science.282.5396.2012;
RG   The C. elegans sequencing consortium;
RT   "Genome sequence of the nematode C. elegans: a platform for investigating
RT   biology.";
RL   Science 282:2012-2018(1998).
RN   [3] {ECO:0000305}
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=14697358; DOI=10.1016/j.ydbio.2003.09.024;
RA   Pang K.M., Ishidate T., Nakamura K., Shirayama M., Trzepacz C.,
RA   Schubert C.M., Priess J.R., Mello C.C.;
RT   "The minibrain kinase homolog, mbk-2, is required for spindle positioning
RT   and asymmetric cell division in early C. elegans embryos.";
RL   Dev. Biol. 265:127-139(2004).
RN   [4]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=16289132; DOI=10.1016/j.ydbio.2005.09.053;
RA   Nishi Y., Lin R.;
RT   "DYRK2 and GSK-3 phosphorylate and promote the timely degradation of OMA-1,
RT   a key regulator of the oocyte-to-embryo transition in C. elegans.";
RL   Dev. Biol. 288:139-149(2005).
RN   [5]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-490.
RX   PubMed=16338136; DOI=10.1016/j.cub.2005.11.063;
RA   Stitzel M.L., Pellettieri J., Seydoux G.;
RT   "The C. elegans DYRK Kinase MBK-2 marks oocyte proteins for degradation in
RT   response to meiotic maturation.";
RL   Curr. Biol. 16:56-62(2006).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, INTERACTION WITH EGG-3, SUBCELLULAR
RP   LOCATION, AND MUTAGENESIS OF LYS-490.
RX   PubMed=17869113; DOI=10.1016/j.cub.2007.08.049;
RA   Stitzel M.L., Cheng K.C., Seydoux G.;
RT   "Regulation of MBK-2/Dyrk kinase by dynamic cortical anchoring during the
RT   oocyte-to-zygote transition.";
RL   Curr. Biol. 17:1545-1554(2007).
RN   [7]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=18854162; DOI=10.1016/j.cell.2008.07.040;
RA   Guven-Ozkan T., Nishi Y., Robertson S.M., Lin R.;
RT   "Global transcriptional repression in C. elegans germline precursors by
RT   regulated sequestration of TAF-4.";
RL   Cell 135:149-160(2008).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, AND DISRUPTION PHENOTYPE.
RX   PubMed=18199581; DOI=10.1242/dev.013425;
RA   Nishi Y., Rogers E., Robertson S.M., Lin R.;
RT   "Polo kinases regulate C. elegans embryonic polarity via binding to DYRK2-
RT   primed MEX-5 and MEX-6.";
RL   Development 135:687-697(2008).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, ACTIVITY REGULATION,
RP   BIOPHYSICOCHEMICAL PROPERTIES, IDENTIFICATION IN A COMPLEX WITH EGG-3;
RP   EGG-4 AND EGG-5, INTERACTION WITH EGG-3; EGG-4 AND EGG-5, SUBCELLULAR
RP   LOCATION, AUTOPHOSPHORYLATION, PHOSPHORYLATION AT SER-362 AND TYR-621, AND
RP   MUTAGENESIS OF SER-362; LYS-490; TYR-619; TYR-621 AND THR-764.
RX   PubMed=19879842; DOI=10.1016/j.cell.2009.08.047;
RA   Cheng K.C., Klancer R., Singson A., Seydoux G.;
RT   "Regulation of MBK-2/DYRK by CDK-1 and the pseudophosphatases EGG-4 and
RT   EGG-5 during the oocyte-to-embryo transition.";
RL   Cell 139:560-572(2009).
RN   [10]
RP   FUNCTION, CATALYTIC ACTIVITY, AND DISRUPTION PHENOTYPE.
RX   PubMed=25535836; DOI=10.7554/elife.04591;
RA   Wang J.T., Smith J., Chen B.C., Schmidt H., Rasoloson D., Paix A.,
RA   Lambrus B.G., Calidas D., Betzig E., Seydoux G.;
RT   "Regulation of RNA granule dynamics by phosphorylation of serine-rich,
RT   intrinsically disordered proteins in C. elegans.";
RL   Elife 3:e04591-e04591(2014).
CC   -!- FUNCTION: Required for oocyte-to-zygote transition in which it
CC       phosphorylates oocyte proteins, including mei-1, oma-1, oma-2, mex-5,
CC       and mex-6, modifying their activity and/or stability following meiosis
CC       (PubMed:16289132, PubMed:16338136, PubMed:17869113, PubMed:18199581,
CC       PubMed:18854162, PubMed:19879842). Through phosphorylation of P granule
CC       components including meg-1, promotes the disassembly of zygotic P
CC       granules in the anterior cytoplasm during zygote polarization, and thus
CC       plays a role in P granule distribution and segregation in early stage
CC       embryos following meiosis (PubMed:25535836). Functions in both spindle
CC       positioning and in the posterior localization of cytoplasmic
CC       determinants, including pie-1, pos-1, and pgl-1, in early embryos
CC       (PubMed:14697358). Involved in the asymmetric distribution of plk-1 at
CC       the 2-cell embryonic stage (PubMed:18199581).
CC       {ECO:0000269|PubMed:14697358, ECO:0000269|PubMed:16289132,
CC       ECO:0000269|PubMed:16338136, ECO:0000269|PubMed:17869113,
CC       ECO:0000269|PubMed:18199581, ECO:0000269|PubMed:18854162,
CC       ECO:0000269|PubMed:19879842, ECO:0000269|PubMed:25535836}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP +
CC         H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.12.1;
CC         Evidence={ECO:0000269|PubMed:17869113, ECO:0000269|PubMed:18199581,
CC         ECO:0000269|PubMed:19879842, ECO:0000269|PubMed:25535836};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] +
CC         ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA-
CC         COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.12.1;
CC         Evidence={ECO:0000269|PubMed:17869113, ECO:0000269|PubMed:18199581,
CC         ECO:0000269|PubMed:19879842, ECO:0000269|PubMed:25535836};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] +
CC         ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.12.1;
CC         Evidence={ECO:0000269|PubMed:17869113, ECO:0000269|PubMed:18199581,
CC         ECO:0000269|PubMed:19879842};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:17869113, ECO:0000269|PubMed:18199581,
CC         ECO:0000269|PubMed:19879842};
CC   -!- ACTIVITY REGULATION: Activated during oocyte maturation by
CC       phosphorylation on Ser-362 by cdk-1. The pseudotyrosine phosphatases
CC       egg-4 and egg-5 sequester activated mbk-2 until the meiotic divisions
CC       and inhibit mbk-2 kinase activity directly, using a mixed-inhibition
CC       mechanism that does not involve tyrosine dephosphorylation.
CC       {ECO:0000269|PubMed:19879842}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.3 uM for mei-1 (Isoform a) {ECO:0000269|PubMed:19879842};
CC         Note=The presence of egg-4 in the assay increases the KM of mbk-2 for
CC         mei-1. {ECO:0000269|PubMed:19879842};
CC   -!- SUBUNIT: Part of a complex, consisting of pseudophosphatases egg-3,
CC       egg-4, egg-5 and kinase mbk-2; this complex is required for the oocyte-
CC       to-zygote transition (PubMed:19879842). Interacts (via Tyr-619 and Tyr-
CC       621) with egg-4 (via tyrosine-protein phosphatase domain) and egg-5
CC       (via tyrosine-protein phosphatase domain); mbk-2 tyrosine
CC       phosphorylation enhances the interaction (PubMed:19879842). The
CC       interaction inhibits mbk-2 kinase activity and is required for mbk-2
CC       oocyte cortex localization. Interacts (via N-terminus) with egg-3 (via
CC       tyrosine-protein phosphatase domain); the interaction does not affect
CC       mbk-2 kinase activity, is enhanced by mbk-2 tyrosine phosphorylation
CC       status and requires prior binding of mbk-2 to egg-4 and egg-5
CC       (PubMed:17869113, PubMed:19879842). {ECO:0000269|PubMed:17869113,
CC       ECO:0000269|PubMed:19879842}.
CC   -!- INTERACTION:
CC       Q9XTF3; Q20402: egg-3; NbExp=9; IntAct=EBI-2005616, EBI-2476895;
CC       Q9XTF3-2; P34808: mei-1; NbExp=2; IntAct=EBI-2565597, EBI-323248;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cell cortex
CC       {ECO:0000269|PubMed:12618396, ECO:0000269|PubMed:16338136,
CC       ECO:0000269|PubMed:17869113, ECO:0000269|PubMed:18854162}.
CC       Note=Maintained at the cortex by the cortical anchor egg-3 before
CC       meiotic divisions. During anaphase of meiosis I, egg-3 translocates
CC       into the cytoplasm on vesicles and is slowly degraded, releasing mbk-2.
CC       {ECO:0000269|PubMed:12618396, ECO:0000269|PubMed:16338136,
CC       ECO:0000269|PubMed:17869113, ECO:0000269|PubMed:19879842}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=8;
CC       Name=b {ECO:0000269|PubMed:9851916};
CC         IsoId=Q9XTF3-1; Sequence=Displayed;
CC       Name=a {ECO:0000269|PubMed:9851916};
CC         IsoId=Q9XTF3-2; Sequence=VSP_053183, VSP_053184, VSP_053186;
CC       Name=c {ECO:0000269|PubMed:12618396, ECO:0000269|PubMed:9851916};
CC         IsoId=Q9XTF3-3; Sequence=VSP_053187;
CC       Name=d {ECO:0000269|PubMed:9851916};
CC         IsoId=Q9XTF3-4; Sequence=VSP_053181, VSP_053186;
CC       Name=e {ECO:0000269|PubMed:9851916};
CC         IsoId=Q9XTF3-5; Sequence=VSP_053182, VSP_053185, VSP_053186;
CC       Name=f;
CC         IsoId=Q9XTF3-6; Sequence=VSP_053625, VSP_053628, VSP_053629,
CC                                  VSP_053630;
CC       Name=g;
CC         IsoId=Q9XTF3-7; Sequence=VSP_053627;
CC       Name=h;
CC         IsoId=Q9XTF3-8; Sequence=VSP_053626;
CC   -!- TISSUE SPECIFICITY: In L1 larvae, expressed widely in the nervous
CC       system, including head neurons and the ventral nerve cord. In adult
CC       animals, continues to be expressed in the nervous system and is also
CC       expressed in body wall muscle. {ECO:0000269|PubMed:12618396}.
CC   -!- DEVELOPMENTAL STAGE: Expressed both maternally and zygotically.
CC       {ECO:0000269|PubMed:12618396}.
CC   -!- PTM: Autophosphorylated. {ECO:0000269|PubMed:19879842}.
CC   -!- DISRUPTION PHENOTYPE: Maternal-effect embryonic lethality due to
CC       defects in spindle positioning and cytokinesis in the early embryo
CC       (PubMed:12618396, PubMed:14697358). Microtubules are fragmented and
CC       disordered (PubMed:14697358). Abolishes phosphorylation of RNA-binding
CC       protein oma-1 in embryos (PubMed:16289132). RNAi-mediated knockdown
CC       causes an increase in taf-4 nuclear localization in the one-cell embryo
CC       (PubMed:18854162). RNAi-mediated knockdown causes a loss in plk-1
CC       asymmetric localization in 2-cell stage embryo without affecting mex-5
CC       polarization (PubMed:18199581). RNAi-mediated knockdown disrupts P
CC       granule distribution in zygotes after meiosis whereby zygotic P
CC       granules fail to disassemble in the anterior cytoplasm during zygote
CC       polarization, however new P granules assemble and accumulate in the
CC       posterior cytoplasm as in wild-type (PubMed:25535836).
CC       {ECO:0000269|PubMed:12618396, ECO:0000269|PubMed:14697358,
CC       ECO:0000269|PubMed:16289132, ECO:0000269|PubMed:18199581,
CC       ECO:0000269|PubMed:18854162, ECO:0000269|PubMed:25535836}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr
CC       protein kinase family. MNB/DYRK subfamily. {ECO:0000255}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY090019; AAM09088.1; -; mRNA.
DR   EMBL; Z70308; CAA94352.1; -; Genomic_DNA.
DR   EMBL; Z70308; CAA94353.1; -; Genomic_DNA.
DR   EMBL; Z81121; CAA94353.1; JOINED; Genomic_DNA.
DR   EMBL; Z81146; CAA94353.1; JOINED; Genomic_DNA.
DR   EMBL; Z70308; CAB54254.2; -; Genomic_DNA.
DR   EMBL; Z81121; CAB54254.2; JOINED; Genomic_DNA.
DR   EMBL; Z81146; CAB54254.2; JOINED; Genomic_DNA.
DR   EMBL; Z70308; CAJ76942.1; -; Genomic_DNA.
DR   EMBL; Z70308; CAJ80814.1; -; Genomic_DNA.
DR   EMBL; Z81121; CAJ80814.1; JOINED; Genomic_DNA.
DR   EMBL; Z70308; CCG28133.1; -; Genomic_DNA.
DR   EMBL; Z81121; CCG28133.1; JOINED; Genomic_DNA.
DR   EMBL; Z81146; CCG28133.1; JOINED; Genomic_DNA.
DR   EMBL; Z70308; CCG28134.1; -; Genomic_DNA.
DR   EMBL; Z81121; CCG28134.1; JOINED; Genomic_DNA.
DR   EMBL; Z70308; CCM09396.1; -; Genomic_DNA.
DR   EMBL; Z81121; CCM09396.1; JOINED; Genomic_DNA.
DR   PIR; T22440; T22440.
DR   PIR; T22442; T22442.
DR   RefSeq; NP_001023207.1; NM_001028036.5. [Q9XTF3-1]
DR   RefSeq; NP_001023208.1; NM_001028037.4. [Q9XTF3-3]
DR   RefSeq; NP_001040950.1; NM_001047485.5. [Q9XTF3-4]
DR   RefSeq; NP_001040951.1; NM_001047486.4. [Q9XTF3-5]
DR   RefSeq; NP_001255694.1; NM_001268765.1.
DR   RefSeq; NP_001255695.1; NM_001268766.4. [Q9XTF3-6]
DR   RefSeq; NP_001263802.1; NM_001276873.1.
DR   RefSeq; NP_001366773.1; NM_001380500.1. [Q9XTF3-2]
DR   RefSeq; NP_001368118.1; NM_001380497.1. [Q9XTF3-7]
DR   RefSeq; NP_001368149.1; NM_001380498.1. [Q9XTF3-8]
DR   RefSeq; NP_502492.2; NM_070091.6.
DR   AlphaFoldDB; Q9XTF3; -.
DR   SMR; Q9XTF3; -.
DR   BioGRID; 43342; 132.
DR   ComplexPortal; CPX-3381; Egg-3/4/5 MBK-2 complex.
DR   FunCoup; Q9XTF3; 154.
DR   IntAct; Q9XTF3; 11.
DR   STRING; 6239.F49E11.1b.1; -.
DR   iPTMnet; Q9XTF3; -.
DR   PaxDb; 6239-F49E11.1b; -.
DR   PeptideAtlas; Q9XTF3; -.
DR   EnsemblMetazoa; F49E11.1a.1; F49E11.1a.1; WBGene00003150. [Q9XTF3-2]
DR   EnsemblMetazoa; F49E11.1b.1; F49E11.1b.1; WBGene00003150. [Q9XTF3-1]
DR   EnsemblMetazoa; F49E11.1c.1; F49E11.1c.1; WBGene00003150. [Q9XTF3-3]
DR   EnsemblMetazoa; F49E11.1d.1; F49E11.1d.1; WBGene00003150. [Q9XTF3-4]
DR   EnsemblMetazoa; F49E11.1e.1; F49E11.1e.1; WBGene00003150. [Q9XTF3-5]
DR   EnsemblMetazoa; F49E11.1f.1; F49E11.1f.1; WBGene00003150. [Q9XTF3-6]
DR   EnsemblMetazoa; F49E11.1g.1; F49E11.1g.1; WBGene00003150. [Q9XTF3-7]
DR   EnsemblMetazoa; F49E11.1h.1; F49E11.1h.1; WBGene00003150. [Q9XTF3-8]
DR   GeneID; 178250; -.
DR   KEGG; cel:CELE_F49E11.1; -.
DR   UCSC; F49E11.1c; c. elegans.
DR   AGR; WB:WBGene00003150; -.
DR   CTD; 178250; -.
DR   WormBase; F49E11.1a; CE05897; WBGene00003150; mbk-2. [Q9XTF3-2]
DR   WormBase; F49E11.1b; CE19878; WBGene00003150; mbk-2. [Q9XTF3-1]
DR   WormBase; F49E11.1c; CE23751; WBGene00003150; mbk-2. [Q9XTF3-3]
DR   WormBase; F49E11.1d; CE39735; WBGene00003150; mbk-2. [Q9XTF3-4]
DR   WormBase; F49E11.1e; CE39938; WBGene00003150; mbk-2. [Q9XTF3-5]
DR   WormBase; F49E11.1f; CE47098; WBGene00003150; mbk-2. [Q9XTF3-6]
DR   WormBase; F49E11.1g; CE47427; WBGene00003150; mbk-2. [Q9XTF3-7]
DR   WormBase; F49E11.1h; CE47790; WBGene00003150; mbk-2. [Q9XTF3-8]
DR   eggNOG; KOG0667; Eukaryota.
DR   GeneTree; ENSGT00940000166363; -.
DR   InParanoid; Q9XTF3; -.
DR   OMA; CTATSMP; -.
DR   OrthoDB; 9332038at2759; -.
DR   PhylomeDB; Q9XTF3; -.
DR   SignaLink; Q9XTF3; -.
DR   PRO; PR:Q9XTF3; -.
DR   Proteomes; UP000001940; Chromosome IV.
DR   Bgee; WBGene00003150; Expressed in pharyngeal muscle cell (C elegans) and 4 other cell types or tissues.
DR   ExpressionAtlas; Q9XTF3; baseline and differential.
DR   GO; GO:0005938; C:cell cortex; IDA:UniProtKB.
DR   GO; GO:0005813; C:centrosome; IDA:WormBase.
DR   GO; GO:0005694; C:chromosome; IDA:WormBase.
DR   GO; GO:0000793; C:condensed chromosome; IDA:WormBase.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; IBA:GO_Central.
DR   GO; GO:0072686; C:mitotic spindle; IDA:WormBase.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0043186; C:P granule; IDA:WormBase.
DR   GO; GO:0005524; F:ATP binding; ISS:WormBase.
DR   GO; GO:0004672; F:protein kinase activity; IDA:WormBase.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:WormBase.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IMP:UniProtKB.
DR   GO; GO:0045167; P:asymmetric protein localization involved in cell fate determination; IMP:WormBase.
DR   GO; GO:0009792; P:embryo development ending in birth or egg hatching; IMP:WormBase.
DR   GO; GO:0009880; P:embryonic pattern specification; IMP:WormBase.
DR   GO; GO:0007017; P:microtubule-based process; IMP:WormBase.
DR   GO; GO:0000281; P:mitotic cytokinesis; IMP:WormBase.
DR   GO; GO:0001556; P:oocyte maturation; NAS:ComplexPortal.
DR   GO; GO:1903864; P:P granule disassembly; IMP:WormBase.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IMP:UniProtKB.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IMP:WormBase.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; IMP:WormBase.
DR   CDD; cd14224; PKc_DYRK2_3; 1.
DR   FunFam; 1.10.510.10:FF:000112; Putative dual specificity tyrosine-phosphorylation-regulated kinase 2; 1.
DR   FunFam; 3.30.200.20:FF:000127; Putative dual specificity tyrosine-phosphorylation-regulated kinase 2; 1.
DR   Gene3D; 3.30.10.30; DYRK; 1.
DR   Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1.
DR   Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1.
DR   InterPro; IPR042521; DYRK.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR050494; Ser_Thr_dual-spec_kinase.
DR   PANTHER; PTHR24058; DUAL SPECIFICITY PROTEIN KINASE; 1.
DR   PANTHER; PTHR24058:SF112; DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 3 HOMOLOG-RELATED; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cytoplasm; Developmental protein;
KW   Kinase; Magnesium; Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Tyrosine-protein kinase.
FT   CHAIN           1..817
FT                   /note="Dual specificity tyrosine-phosphorylation-regulated
FT                   kinase mbk-2"
FT                   /id="PRO_0000390717"
FT   DOMAIN          461..774
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..46
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          70..148
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          186..206
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          301..396
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        7..25
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        70..81
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        97..111
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        122..143
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        193..206
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        303..318
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        327..351
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        364..392
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        587
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250|UniProtKB:P28523,
FT                   ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE-
FT                   ProRule:PRU10027"
FT   BINDING         467..475
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P28523,
FT                   ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         490
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000269|PubMed:16338136, ECO:0000269|PubMed:17869113,
FT                   ECO:0000269|PubMed:19879842"
FT   MOD_RES         362
FT                   /note="Phosphoserine; by cdk-1"
FT                   /evidence="ECO:0000269|PubMed:19879842"
FT   MOD_RES         621
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000305|PubMed:19879842"
FT   VAR_SEQ         1..327
FT                   /note="Missing (in isoform d)"
FT                   /evidence="ECO:0000303|PubMed:9851916"
FT                   /id="VSP_053181"
FT   VAR_SEQ         1..301
FT                   /note="Missing (in isoform e)"
FT                   /evidence="ECO:0000303|PubMed:9851916"
FT                   /id="VSP_053182"
FT   VAR_SEQ         1..297
FT                   /note="Missing (in isoform f)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_053625"
FT   VAR_SEQ         1..294
FT                   /note="Missing (in isoform a)"
FT                   /evidence="ECO:0000303|PubMed:9851916"
FT                   /id="VSP_053183"
FT   VAR_SEQ         1..282
FT                   /note="Missing (in isoform h)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_053626"
FT   VAR_SEQ         148..164
FT                   /note="Missing (in isoform g)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_053627"
FT   VAR_SEQ         295..310
FT                   /note="AAQATGLPNVGTSSSN -> MTLFEPSTSGNRMGYR (in isoform a)"
FT                   /evidence="ECO:0000303|PubMed:9851916"
FT                   /id="VSP_053184"
FT   VAR_SEQ         298..310
FT                   /note="ATGLPNVGTSSSN -> MFAIPFHRFYSDE (in isoform f)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_053628"
FT   VAR_SEQ         302..310
FT                   /note="PNVGTSSSN -> MYSSLFELR (in isoform e)"
FT                   /evidence="ECO:0000303|PubMed:9851916"
FT                   /id="VSP_053185"
FT   VAR_SEQ         797..817
FT                   /note="KKTETLPNIDSNANILMRKKF -> VCFIIF (in isoform a,
FT                   isoform d and isoform e)"
FT                   /evidence="ECO:0000303|PubMed:9851916"
FT                   /id="VSP_053186"
FT   VAR_SEQ         797..817
FT                   /note="Missing (in isoform c)"
FT                   /evidence="ECO:0000303|PubMed:12618396,
FT                   ECO:0000303|PubMed:9851916"
FT                   /id="VSP_053187"
FT   VAR_SEQ         797..802
FT                   /note="KKTETL -> VCFIIF (in isoform f)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_053629"
FT   VAR_SEQ         803..817
FT                   /note="Missing (in isoform f)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_053630"
FT   MUTAGEN         362
FT                   /note="S->A: Loss of phosphorylation by cdk-1. Loss of
FT                   kinase activity."
FT                   /evidence="ECO:0000269|PubMed:19879842"
FT   MUTAGEN         362
FT                   /note="S->E: Constitutively active."
FT                   /evidence="ECO:0000269|PubMed:19879842"
FT   MUTAGEN         490
FT                   /note="K->R: Loss of autophosphorylation activity. Slight
FT                   loss of binding to egg-4 and egg-5."
FT                   /evidence="ECO:0000269|PubMed:16338136,
FT                   ECO:0000269|PubMed:17869113, ECO:0000269|PubMed:19879842"
FT   MUTAGEN         619
FT                   /note="Y->F: Reduced binding to egg-4 and egg-5 and
FT                   translocation to the cytoplasm; when associated with
FT                   F-621."
FT                   /evidence="ECO:0000269|PubMed:19879842"
FT   MUTAGEN         621
FT                   /note="Y->F: Loss of tyrosine phosphorylation. Reduced
FT                   binding to egg-4 and egg-5 and translocation to the
FT                   cytoplasm; when associated with F-619."
FT                   /evidence="ECO:0000269|PubMed:19879842"
FT   MUTAGEN         764
FT                   /note="T->A: No loss of phosphorylation by cdk-1."
FT                   /evidence="ECO:0000269|PubMed:19879842"
SQ   SEQUENCE   817 AA;  89885 MW;  74903C85CB68C428 CRC64;
     MAALASFTRN SRSYGQQPID VTQQGQRDRS VMSLDAQGRS VSHECPTSTT LVRQLYLPQI
     PQSASFAAAP TSFSGASSSS SNHHHPVYHS QNSLPPNLLG SSQNSASSNS LVQGHRNPAL
     GSGNTLTRSY HQPSSTNSST NNLYGPLGTI SRDLKQSIRD ISPPVINSSA NPHLVNYVQT
     SSFDNGSYEF PSGQAQQQRR LGGSQQHLAP LQQTASSLYS NPQSSSSQLL GQQQAVRPNY
     AYQQSLPRQQ HINSHQTQAF FGTVRGPTNS TNIVTPLRAS KTMIDVLAPV RDTVAAQATG
     LPNVGTSSSN GSSNSSSGVG SGGSGSLMTQ SIGGPNKHLS ASHSTLNTAS THDMMHSKIP
     KSPSNESLSR SHTSSSGGSQ GGHNSNSGSN SGFRPEDAVQ TFGAKLVPFE KNEIYNYTRV
     FFVGSHAKKQ AGVIGGANNG GYDDENGSYQ LVVHDHIAYR YEVLKVIGKG SFGQVIKAFD
     HKYQQYVALK LVRNEKRFHR QADEEIRILD HLRRQDSDGT HNIIHMLDYF NFRNHKCITF
     ELLSINLYEL IKRNKFQGFS LMLVRKFAYS MLLCLDLLQK NRLIHCDLKP ENVLLKQQGR
     SGIKVIDFGS SCFDDQRIYT YIQSRFYRAP EVILGTKYGM PIDMWSLGCI LAELLTGYPL
     LPGEDENDQL ALIIELLGMP PPKSLETAKR ARTFITSKGY PRYCTATSMP DGSVVLAGAR
     SKRGKMRGPP ASRSWSTALK NMGDELFVDF LKRCLDWDPE TRMTPAQALK HKWLRRRLPN
     PPRDGLESMG GLADHEKKTE TLPNIDSNAN ILMRKKF
//
